Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 31

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 31
---
ization of complex autologous cell therapies,
we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we
are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the
initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase and
profitability could be further delayed.

Even if we achieve profitability,
we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would
depress the value of our securities and could impair our ability to raise capital, expand our business, maintain our R&D efforts
or continue our operations. A decline in the value of our securities could also cause you to lose all or part of your investment.

<div align='center'>11</div>

Our independent registered public accountants have expressed substantial doubt as to our ability to continue as a going concern.

In its report on our financial
statements for the year ended December 31, 2023, our independent registered public accounting firm included an explanatory paragraph
that expressed substantial doubt about our ability to continue as a going concern. Our current cash level raises substantial doubt about
our ability to continue as a going concern. In addition, our future financial statements may include similar qualifications about our
ability to continue as a going concern. Our financial statements were prepared assuming that we will continue as a going concern and
do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to meet our current operating costs,
we will need to seek additional financing or modify or cease our operational plans. If we seek additional financing to fund our business
activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing
sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.

Our limited operating history makes it difficult to evaluate our business and assess our future viability and prospects.

We are a preclinical stage
company with a limited operating history. We commenced operations in 2016, and our operations to date have been limited to organizing
and planning our development efforts, raising capital, conducting discovery and research activities, filing patent applications, identifying
potential product candidates, undertaking preclinical studies, and establishing arrangements with third parties for the manufacture of
initial quantities of CER-1236 and component materials. We have not yet demonstrated our